Wells Fargo & Company Standard Biotools Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Standard Biotools Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 133,531 shares of LAB stock, worth $261,720. This represents 0.0% of its overall portfolio holdings.
Number of Shares
133,531
Previous 11,207
1091.5%
Holding current value
$261,720
Previous $30,000
686.67%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding LAB
# of Institutions
148Shares Held
269MCall Options Held
422KPut Options Held
40.7K-
Casdin Capital, LLC New York, NY64MShares$125 Million9.8% of portfolio
-
Viking Global Investors LP58.7MShares$115 Million0.41% of portfolio
-
Black Rock Inc. New York, NY21.8MShares$42.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16MShares$31.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY12.9MShares$25.4 Million0.0% of portfolio
About STANDARD BIOTOOLS INC.
- Ticker LAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 78,654,800
- Market Cap $154M
- Description
- Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar ...